Edap Tms (NASDAQ:EDAP - Get Free Report) announced its earnings results on Thursday. The medical equipment provider reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.06, Zacks reports. Edap Tms had a negative return on equity of 44.21% and a negative net margin of 34.92%. The business had revenue of $22.69 million for the quarter, compared to the consensus estimate of $20.83 million.
Edap Tms Stock Down 2.1 %
Shares of EDAP traded down $0.05 on Monday, hitting $2.11. The company's stock had a trading volume of 38,843 shares, compared to its average volume of 86,418. The company has a quick ratio of 1.46, a current ratio of 2.18 and a debt-to-equity ratio of 0.08. The firm has a market capitalization of $78.10 million, a price-to-earnings ratio of -3.24 and a beta of 0.37. The firm's fifty day moving average price is $2.42 and its 200-day moving average price is $2.50. Edap Tms has a fifty-two week low of $1.96 and a fifty-two week high of $8.50.
Analyst Upgrades and Downgrades
Several research firms have weighed in on EDAP. Piper Sandler cut their target price on Edap Tms from $5.00 to $4.50 and set an "overweight" rating on the stock in a research note on Friday. StockNews.com initiated coverage on shares of Edap Tms in a research note on Friday. They issued a "hold" rating for the company. Finally, HC Wainwright reissued a "buy" rating and set a $19.00 price target on shares of Edap Tms in a research report on Friday.
View Our Latest Stock Analysis on EDAP
Edap Tms Company Profile
(
Get Free Report)
EDAP TMS SA is a holding company, which, through its subsidiary, engages in the development, production, and marketing of minimally invasive medical devices for urological diseases. It operates through the High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS) segments. The HIFU segment develops, manufactures, and markets devices for the minimally invasive ablation of certain types of localized tumors using HIFU technology.
See Also
Before you consider Edap Tms, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Edap Tms wasn't on the list.
While Edap Tms currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
